Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Schrödinger, Inc. SDGR
$26.18
-$0.34 (-1.31%)
На 18:02, 12 мая 2023
-12.15%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1942394543.00000000
-
week52high
35.24
-
week52low
15.85
-
Revenue
180955000
-
P/E TTM
-13
-
Beta
1.05209200
-
EPS
-2.20000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 26 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 05 мая 2022 г. |
| Citigroup | Buy | 01 мар 2022 г. | |
| Piper Sandler | Overweight | 19 ноя 2021 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 ноя 2022 г. |
| BMO Capital | Outperform | Outperform | 04 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 янв 2023 г. |
| Citigroup | Buy | Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tran Yvonne | D | 108 | 13269 | 02 февр 2023 г. |
| Tran Yvonne | D | 0 | 11731 | 02 февр 2023 г. |
| Tran Yvonne | D | 5131 | 25000 | 02 февр 2023 г. |
| Tran Yvonne | A | 30131 | 13269 | 02 февр 2023 г. |
| Tran Yvonne | A | 16862 | 11731 | 02 февр 2023 г. |
| Farid Ramy | D | 0 | 66886 | 04 янв 2023 г. |
| Farid Ramy | D | 184432 | 66886 | 04 янв 2023 г. |
| Farid Ramy | A | 251318 | 66886 | 04 янв 2023 г. |
| Porges Geoffrey Craig | A | 180000 | 180000 | 18 авг 2022 г. |
| Thornberry Nancy | D | 41870 | 4950 | 11 авг 2022 г. |
Новостная лента
Schrodinger: Unlocking The Potential Of Computer-Assisted Drug Discovery During Tough Times
Seeking Alpha
24 янв 2023 г. в 08:28
Schrodinger has developed a software platform that uses advanced physics and machine learning methods to predict important aspects of molecules with high accuracy. Their platform can help find new drugs faster and cheaper and increase the chances of success in further testing.
Schrodinger: Solving The Critical Need For AI/ML In The Biopharma Industry
Seeking Alpha
21 янв 2023 г. в 23:46
SDGR's valuable segment is its software business which represents majority of the revenue. There is an increasing demand for AI/ML capabilities by biopharmaceutical companies.
Why These 7 Healthcare Stocks Could Soar in 2023
InvestorPlace
02 янв 2023 г. в 07:22
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.
7 Drug Stocks That Will Soar in 2023
InvestorPlace
22 дек 2022 г. в 06:00
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.
Schrodinger: Upgrading My Rating Post The Recent Nimbus Deal
Seeking Alpha
19 дек 2022 г. в 08:15
Schrodinger stock saw a good jump last week post Nimbus Takeda deal. In addition to immediate benefits, the deal also signals strong long-term prospects for the company's drug discovery collaboration business.